True COVID-19 mortality rates from administrative data.

In this paper, I use administrative data to estimate the number of deaths, the number of infections, and mortality rates from COVID-19 in Lombardia, the hot spot of the disease in Italy and Europe. The information will assist policy makers in reaching correct decisions and the public in adopting appropriate behaviors. As the available data suffer from sample selection bias, I use partial identification to derive the above quantities.

Explaining the causal effect of adherence to medication on cholesterol through the marginal patient.

This paper investigates the relation between adherence to prescribed medication and reduction of cholesterol in Italy, taking into account the possible sorting of patients into treatment and the heterogeneity of the effect. As predicted by a theoretical model, I find that patients who benefit most from medication are more likely to adhere to prescribed regime than those who benefit least. These results are used to study the effects of three hypothetical policies that aim at increasing the share of patients adherent to prescribed medication: one policy is directed toward patients, one toward physicians, and one toward both patients and physicians.

Drug therapy adherence and health outcomes in the presence of physician and patient unobserved heterogeneity.

Understanding the role that drug adherence has on health outcomes in everyday clinical practice is central for the policy maker. This is particularly true when patients suffer from asymptomatic chronic conditions (e.g.

Drug compliance, co-payment and health outcomes: evidence from a panel of Italian patients.

This paper studies the relationship between medical compliance and health outcomes - hospitalization and mortality rates - using a large panel of patients residing in a local health authority in Italy. These data allow us to follow individual patients through all their accesses to public health care services until they either die or leave the local health authority. We adopt a disease specific approach, concentrating on hypertensive patients treated with ACE-inhibitors.